Excerpt from Neuroacanthocytosis SyndromesSynonyms, Key Words, and Related Terms: acanthocytosis, spiked red blood cells, chorea, orofacial tics, amyotrophy, hyper-CKemia, normobetalipoproteinemia, chorea-acanthocytosis, degeneration of the basal ganglia, classic adult neuroacanthocytosis disorder, neuroacanthocytosis variant, NA, Bassen-Kornzweig syndrome, neuroacanthocytosis syndromes Please click here to view the full topic text: Neuroacanthocytosis SyndromesBackgroundNeuroacanthocytosis (NA) syndromes include combined features of acanthocytosis (ie, spiked red blood cells), chorea, orofacial tics, amyotrophy often with hyperCKemia, and normobetalipoproteinemia. NA has been described as inherited as an autosomal recessive disorder, as an autosomal dominant disorder, and as part of an X-linked disorder called McLeod syndrome (MLS). The autosomal recessive type, usually called chorea-acanthocytosis, is most common and was originally described by Levine and Critchley in the 1960s. In 2001, the gene for this recessive type was characterized on chromosome 9. Since that year, rarer autosomal dominant disease forms with variable penetrance with or without chromosome 9 abnormalities have also been described. In all types, the neurologic course is progressive. Degeneration of the basal ganglia is a consistent feature of this disorder. All of the syndromes under the NA umbrella are distinguished from the Bassen-Kornzweig syndrome, an autosomal recessive disorder of childhood in which abetalipoproteinemia and acanthocytosis occur along with steatorrhea, retinitis pigmentosa, and cerebellar ataxia. Acanthocytosis has also been associated with the rare hypobetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP) syndrome, a disease of childhood akin to Hallervorden-Spatz disease and a defect in the gene for pantothenate kinase. The array of clinical features in NA syndromes is complex. Not only are cases known in which neurologic features of classic adult and childhood acanthocytosis syndromes overlap, but adult forms have been well described in which lipid profiles more closely resemble those of Bassen-Kornzweig syndrome, as have adult forms that begin in childhood.
In a detailed pathophysiological study, the well-described choreiform movement disorder of NA has been described coexisting with an associated peripheral neuropathy in a patient without acanthocytosis. PathophysiologyThe precise pathophysiology is not understood. Clues to the pathogenesis of the disorder arise from the observation that both the neurological and hematological systems are affected. In the classic form of the disorder, central nervous system pathologic features include atrophy of the caudate and putamen and, to a lesser extent, the globus pallidus and substantia nigra. A cell loss of 90% in the striatum with astrocytic gliosis has been reported. In contrast to Huntington disease (HD), the major inherited choreiform disorder of adults, the cerebral cortex and corpus callosum is relatively spared. Additionally, the presence of acanthocytosis distinguishes NA from HD.
Other common sites of pathophysiological dysfunction are the spinal cord, muscles, and nerves.
Both RBC membrane protein and lipid abnormalities have been described, notably in the critical band 3 protein layer (most recently in the Walker family) and in an abnormal composition of covalently bound fatty acids. Antibodies to the GM1 ganglioside component of peripheral nerves have been described. This GM1 ganglioside is also present in RBC membranes and in the central nervous system. Decreases in GM3 and sialoparagloboside components of RBC membranes have been noted. These gangliosides are also present throughout the nervous system. Many of the patients with McLeod syndrome have cardiomyopathy or hemolytic anemia, features not as commonly noted in the autosomal cases. Recently, Redman and Reid have commented on the complexity of the Kell blood group proteins whereby the Kell protein expressed via a gene on chromosome 7 interacts with the XK protein, strikingly absent in patients with McLeod syndrome. These proteins are preferentially expressed in erythroid tissue but are also present in lesser amounts in brain and skeletal and cardiac muscle. The Kell protein is essential in the activation of the endothelin system and is important in cell membrane integrity. The XK protein bound to it in a 2-protein complex may have a complementary role as a membrane transporter. Experimental evidence cited by van den Buuse and Webber suggests endothelins may be basal ganglia neurotransmitters. Thus, the implication exists for a neurochemical tie to the NA syndromes, so often highlighted by basal ganglia dysfunction. In two recent reviews, Bosman and De Franceschi and Corrocher have also summarized several studies of non-McLeod NA that have shown abnormalities in the aforementioned band 3 region. Changes in band 3 structure do not only lead to alterations in erythrocyte shape but also to altered anion transport characteristics and increased age-related autoimmunoreactivity, with anti-band 3 antibodies noted in patients with NA. Elaborating on this latter point, echinocytes are normally aging misshapen RBCs reported to have band 3 abnormalities as well. Brain band 3 change is also tied to neuronal degeneration and has been linked generally to extrapyramidal movement disorders and axonal neuropathies. These insights, though incompletely understood, suggest that the pathophysiology of all of the NA syndromes involves different gene abnormalities that can cause multisystem membrane defects. The common derangement is in the malformation of the RBC shape and the induction of various levels of central nervous system, neuromuscular, and cardiac dysfunction. Intriguingly is the prospect that some kind of accelerated senescence and autoimmune damage to both erythrocytes and nerve tissue holds a key in fully appreciating the triggering of acanthocytosis and neurodegeneration in NA syndromes. Mindful that the neuroacanthocytotic McLeod syndrome and a recently described non-McLeod NA family with no typical autosomal recessive gene NA defect are not due to a specific chorein protein abnormalities, it is still extremely important to expand our knowledge of chorein, the protein specifically linked to most cases of NA. Dobson-Stone suggests the CHAC or chorein gene locus is abnormal in many ways to induce NA by either not producing gene product or yielding a truncated nonfunctional protein. However, beyond being involved in protein-protein trafficking, how this protein leads to malconfigured erythrocytes and the array of neuropathological and clinical signs of NA is not clear. Many issues in NA and MLS are still unresolved, not the least of which is why these 2 disorders present syndromes that are so similar, despite showing distinct genetic defects. Why the genetic defects in NA and MLS induce hematologic, cardiac, and neurologic abnormalities is also not clear. FrequencyUnited StatesNA syndromes have been described in consanguineous and nonconsanguineous families of English and Puerto Rican descent. InternationalNA syndromes have been described in Japanese, South-African black, Mexican, British, Spanish, Australian, Indian, Italian, German, Scandinavian, French-Canadian, and French populations. Mortality/Morbidity
RaceNA syndromes have been described in all races. Sex
Age
Please click here to view the full topic text: Neuroacanthocytosis Syndromes |
| About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|
|||
|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |